Pilot study to evaluate the effect of Hippocampal Avoidance Technique for Whole Brain Radiotherapy on neurocognitive function in patients with stage IV breast cancer with brain metastases

Genesis Care0 个研究点目标入组 1 人开始时间: 2017年1月25日最近更新: 2019年1月28日

适应症

试验速览

暂无简介。

•1)Signed informed consent
•2)Pathologically proven diagnosis of breast cancer
•3)Stage IV disease with brain metastases which are outside of a 5 mm margin around either hippocampus
•4)Stable or responsive extracranial disease as assessed by the patient’s medical oncologist
•5)ECOG 0-2
•6)Suitable for treatment with WBRT
•7)Non-pregnant women aged over 18 years
•8)Patients able to sufficiently cooperate with the proposed study requirements
•9)Brain metastases that have previously been managed with surgical resection or stereotactic radiosurgery are permitted

•1)Life expectancy anticipated to be equal to or less than 12 weeks
•2)Brain metastases within a 5mm margin of either hippocampus
•3)Leptomeningeal disease
•4)Pregnant women or women of child bearing age who do not wish to use contraception during radiotherapy treatment
•5)Patients with significant psychological or psychiatric comorbidity
•6)All cytotoxic chemotherapy must be withheld from 21 days before starting HAT WBRT, during HAT WBRT delivery and for 30 days after delivery of HAT WBRT

发起方

Genesis Care